Nanogel composition and aerosol delivery
The present invention is directed to a new class of inhalable drug delivery particle gels that are prepared through the assembly of antimycobacterial peptides (AMPs) and FDA approved carbohydrates. Combinatorial therapies can be stably loaded and controllably released without the need for harsh chemicals or cross-linking reactions. After a patient inhales the particles, the technology allows for the recruitment of bacterial pathogens and targeted delivery of loaded AMPs and antibiotics to elicit sustained antimicrobial responses towards drug resistant bacteria. The permeabilization of bacterial membranes by AMPs can enhance the uptake of delivered drugs, thereby increasing their potency. Most AMPs can also be prepared quickly, and at low cost due to their short sequences.
Application & Market Utility
Respiratory diseases such as tuberculosis, pneumonia, and diseases caused by cystic fibrosis are all ailments that can be treated by the present invention. This technology may be particularly suited for treating drug-resistant tuberculosis, which remains one of the leading causes of mortality worldwide. For example, an estimated 2 billion individuals are infected with mycobacterium tuberculosis and current treatments often lead to drug intolerance and toxicity, unwanted drug-drug interactions, and a burdensome length of treatment.
Samples of the technology can be provided. Seeking licensing opportunities and research collaboration. Research is ongoing.